GlassScriptPhysician profile
Thomas G Shetter
NPI 1598756371
$6,131.15
in general payments reported to CMS, 2019-2025
43 companies · $1,098 in 2025
The $1,098 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,598 · 2020: $377 · 2021: $230 · 2022: $186 · 2023: $597 · 2024: $1,046 · 2025: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,724 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,724.37 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $939.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $563.83 | 2020-2025 | Qulipta, Ubrelvy |
| Pfizer INC. | $541.97 | 2019-2025 | |
| Glaxosmithkline, LLC. | $492.80 | 2019-2025 | Trelegy Ellipta, Bexsero, Penmenvy |
| Astrazeneca Pharmaceuticals LP | $460.08 | 2019-2025 | Airsupra, Breztri |
| Amgen INC. | $376.11 | 2019-2025 | Evenity, Otezla, Repatha |
| Lilly USA, LLC | $318.75 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $225.30 | 2019-2024 | Takhzyro |
| Sanofi-Aventis U.S. LLC | $223.97 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.33 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $197.06 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $169.93 | 2019-2025 | Vaxneuvance, Gardasil 9, M-M-R II |
| Novartis Pharmaceuticals Corporation | $142.93 | 2019-2023 | |
| Amarin Pharma, INC. | $138.47 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $89.75 | 2024-2025 | Voquezna |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $83.06 | 2023 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $82.81 | 2019-2025 | Austedo Xr |
| Lundbeck LLC | $82.61 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $75.09 | 2019-2024 | Veozah |
| Abbott Laboratories | $70.05 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Csl Behring | $57.44 | 2020-2023 | Haegarda |
| Vifor Pharma, INC. | $56.04 | 2019-2020 | |
| Eisai INC. | $45.67 | 2020-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.12 | 2023-2025 | Xifaxan, Trulance |
| Allergan, INC. | $40.79 | 2019-2020 | |
| Ethicon INC. | $38.21 | 2025 | Monarch Platform |
| Regeneron Healthcare Solutions, INC. | $37.85 | 2019 | |
| Shield Therapeutics INC | $36.23 | 2023-2025 | Accrufer |
| Inspire Medical Systems, INC. | $31.48 | 2025 | Inspire |
| Otsuka America Pharmaceutical, INC. | $27.52 | 2023-2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $27.01 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $25.61 | 2019-2023 | Eliquis |
| Xeris Pharmaceuticals, INC. | $24.55 | 2024 | Keveyis |
| Medtronic, INC. | $24.52 | 2024 | Inpen Smart Insulin Delivery System |
| Sumitomo Pharma America, INC. | $19.90 | 2024 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $19.16 | 2025 | Zoryve |
| Avanir Pharmaceuticals, INC. | $18.78 | 2019 | |
| Neurelis, INC. | $14.80 | 2023 | Valtoco |
| Ironwood Pharmaceuticals, INC | $14.72 | 2020 | |
| Exact Sciences Corporation | $14.63 | 2025 | Cologuard Collection Kit |
| Grifols USA, LLC | $12.34 | 2020 | |
| Boston Scientific Corporation | $11.77 | 2019 | |
| Daiichi Sankyo INC. | $10.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Shetter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.